Journal of Managed Care & Specialty Pharmacy
Overview
The Journal of Managed Care & Specialty Pharmacy is a peer-reviewed publication that focuses on the intersection of managed care and specialty pharmacy. It provides evidence-based research, clinical reviews, and policy analyses to inform healthcare professionals, payers, and policymakers about the latest advancements and challenges in managing specialty medications within the managed care setting.
Details
Details
Abbr.
J Manag Care Spec Pharm
Start
2014
End
Continuing
Frequency
Monthly
p-ISSN
2376-0540
e-ISSN
2376-1032
Country
United States
Language
English
Specialties
Pharmacology
Pharmacy
Pharmacy
Metrics
Metrics
h-index / Ranks: 4734
75
SJR / Ranks: 5614
766
CiteScore / Ranks: 7633
3.50
JIF / Ranks: 5004
2.1
Recent Articles
1.
McInturff L, Smith S
J Manag Care Spec Pharm
. 2025 Feb;
31(3):245-252.
PMID: 40021469
Background: Asthma is one of the most common chronic respiratory disease states in the United States and poses a large economic burden. The Global Initiative for Asthma updated its clinical...
2.
Enright D, van Duijnhoven E, Ollendorf D, Chambers J
J Manag Care Spec Pharm
. 2025 Feb;
31(3):289-295.
PMID: 40021468
Background: Health technology assessment (HTA) involves a formal review of the clinical, economic, and societal implications of health technologies. Internationally, HTA supports decisions regarding access to novel therapeutics. However, the...
3.
Sullivan S, Chaturvedi S, Gautam P, Arnaud A
J Manag Care Spec Pharm
. 2025 Feb;
31(3):277-288.
PMID: 40021467
Background: Immune thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening thrombotic microangiopathy. Caplacizumab is the only treatment approved by the European Medicines Agency and the US Food and Drug Administration...
4.
Swart E, Peasah S, Huang Y, Bensink M, Greco M, Manolis C, et al.
J Manag Care Spec Pharm
. 2025 Feb;
31(3):236-244.
PMID: 40021466
Background: Migraine prevalence is estimated to be 15% (approximately 50 million people) in the United States, posing a significant burden on the health care system and a top cause of...
5.
Nikitin D, Wasfy J, Winn A, Raymond F, Shah K, Kim S, et al.
J Manag Care Spec Pharm
. 2025 Feb;
31(3):323-328.
PMID: 40021465
No abstract available.
6.
Uyehara N, Nguyen V, Yu S, Weng Y, Son A, Patneedi P, et al.
J Manag Care Spec Pharm
. 2025 Feb;
31(3):306-320.
PMID: 40021464
Background: Oral oncolytic medication adherence is crucial for effective cancer treatment, yet adherence rates vary widely (16%-100%) depending on cancer subtypes, assessment methodologies, and patient contexts. The increased use of...
7.
Coe A, Martindale J, Bynum J
J Manag Care Spec Pharm
. 2025 Feb;
31(3):296-305.
PMID: 40021462
Background: Older adults with Alzheimer disease and related dementias (ADRDs) are at high risk for medication-related problems. Comprehensive medication reviews (CMRs), required in Medicare Part D medication therapy management (MTM)...
8.
Kilgore K, Chan P, Teigland C, Wade S, Mohammadi I
J Manag Care Spec Pharm
. 2025 Feb;
31(3):262-276.
PMID: 40021461
Background: Standard of care (SOC) for relapsed/refractory mantle cell lymphoma (R/R MCL) has included chemoimmunotherapy and targeted therapies (eg, Bruton tyrosine kinase inhibitors [BTKis]). The approval of novel chimeric antigen...
9.
Wyatt H, White S, Holloway H, DeClercq J, Zuckerman A, Choi L, et al.
J Manag Care Spec Pharm
. 2025 Feb;
31(3):253-261.
PMID: 40021460
Background: Oral oncolytic therapy for the management of chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL), such as ibrutinib, acalabrutinib, and venetoclax, have vastly changed CLL treatment. Although effective,...
10.
Sherman B, Sils B, Westrich K
J Manag Care Spec Pharm
. 2025 Feb;
:1-7.
PMID: 39991828
As a major provider of health insurance for working-age Americans, employers can play a significant role in improving the health equity of their employees and family members. In this commentary,...